Regeneron and bluebird bio have announced a partnership to develop six cell therapy drug candidates. https://www.biopharma-reporter.com/Article/2018/08/07/Regeneron-takes-100m-stake-in-bluebird-with-long-view-on-drug-discovery
Although no one really knows what President Trump will do to address high drug prices, Pfizer’s chief executive officer Ian Read said he believes it will crack down on drug rebates. https://www.biospace.com/article/pfizer-s-read-predicts-the-end-of-drug-rebates/
Novo Nordisk is using its digital health portfolio to not only provide resources for patients and providers, but to also … http://www.pm360online.com/novo-nordisk-is-using-real-world-data-from-digital-health-portfolio-to-help-patients/
Before taking over the helm of Novartis AG, Vasant Narasimhan pointed to the harnessing of digital technology as a key method of saving a significant percentage of clinical trial costs. https://www.biospace.com/article/novartis-taps-shyft-analytics-to-drive-company-s-digital-transformation/
Novartis has announced plans to spin off its eye-care unit Alcon into a standalone entity. http://www.pharmatimes.com/news/novartis_to_spin_off_eye_unit_alcon_1242441
Roche has made an offer to buy the remaining shares in cancer genetics firm Foundation Medicine (FMI) for
The post Roche to buy rest of genetics firm Foundation Medicine appeared first on Pharmaphorum. https://pharmaphorum.com/news/roche-buys-shares-foundation-medicine/
Keeping with Sanofi’s traditional focus, the collaboration aims to develop mRNA vaccines for up to five infectious diseases. https://www.biopharmadive.com/news/Sanofi-partner-translate-bio-mrna-vaccines-infectious-disease/525394/
There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and Novartis is one of the companies that is most actively announcing steps to explore this possibility.
In August of last year, the company announced a new position, Chief Digital Officer, and the man to take the position, in Bertrand Bodson.
read more http://www.pharmafile.com/news/517158/novartis-forges-forward-digital-pharma-focalview-app
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients. http://drugdiscovery.pharmaceutical-business-review.com/news/sandoz-pear-to-develop-digital-therapeutics-for-substance-use-disorder-190418-6121611
Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market and has struggled to sell it, is asking out. The British pharma giant will send […] https://www.xconomy.com/boston/2018/04/12/as-novartis-buys-into-gene-therapy-gsk-bows-out-with-orchard-deal/